ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

This study has been completed.
Study NCT00000737.   Last updated on August 22, 2008.   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
Official Title  A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
Brief Summary

To obtain data on the safety of administering megestrol acetate and dronabinol as single agents or in combination to patients with human immunodeficiency virus (HIV)-wasting syndrome. To obtain preliminary data on the efficacy of single agent and combination therapy with megestrol acetate and dronabinol with regard to weight gain, appetite increase and quality of life in this patient population. To obtain steady-state pharmacokinetics data when megestrol acetate and dronabinol are administered as single agents and in combination.

HIV-wasting syndrome, which is characterized by severely debilitating anorexia and weight loss, is of particular concern because it can exacerbate the primary illness and is associated with a poor prognosis. Attempts at maintaining body mass through the use of megestrol acetate and dronabinol, two anti-cachectic drugs, may prolong survival.

Detailed Description

HIV-wasting syndrome, which is characterized by severely debilitating anorexia and weight loss, is of particular concern because it can exacerbate the primary illness and is associated with a poor prognosis. Attempts at maintaining body mass through the use of megestrol acetate and dronabinol, two anti-cachectic drugs, may prolong survival.

Fifty-six patients are randomized to one of four treatment arms, as follows: high-dose megestrol acetate alone; dronabinol alone; high-dose megestrol acetate combined with dronabinol; or low-dose megestrol acetate combined with dronabinol. Treatment continues for 12 weeks. Patients are evaluated for toxicity, preliminary evidence of response (e.g., weight gain), and steady-state pharmacokinetics of drug therapies.

Study Phase Phase I
Study Type  Interventional
Study Design  Treatment, Open Label, Pharmacokinetics Study
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Cachexia
HIV Infections
HIV Wasting Syndrome
Intervention  Drug: Dronabinol
Drug: Megestrol acetate
MEDLINE PMIDs 9071430
Links Click here for more information about Megestrol acetate This link exits the ClinicalTrials.gov site
Click here for more information about Dronabinol This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Completed
Enrollment  56
Start Date 
Completion Date
Eligibility Criteria 

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC). If initiating new antiretroviral therapy, patient must have been on a stable dose for at least 4 weeks prior to study entry.
  • Maintenance or suppressive therapy with any of the following, provided patient has been on a stable dose for at least 1 week prior to study entry:
  • Ganciclovir or foscarnet for CMV retinitis.
  • Fluconazole, amphotericin B, or flucytosine for cryptococcosis.
  • Amphotericin B for disseminated histoplasmosis.
  • Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis.
  • Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex.
  • Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis.
  • Any of the following provided patient is on a stable dose for at least 1 week prior to study entry:
  • Trimethoprim-sulfamethoxazole, aerosolized pentamidine, or dapsone for Pneumocystis carinii prophylaxis.
  • Clotrimazole troches, nystatin suspension, ketoconazole, or fluconazole for oral candidiasis.
  • Oral acyclovir for mucocutaneous herpes simplex.
  • Narcotic analgesics, tranquilizers, sedative-hypnotics, or anticholinergic agents provided patient is on a stable dose for at least 1 week prior to study entry.

Patients must have:

  • HIV infection.
  • HIV-wasting syndrome and anorexia.
  • Life expectancy of at least 4 months.
  • Ability to tolerate oral therapy, feed themselves, and have access to as much food as they desire with no dietary restrictions.

Prior Medication:

Allowed:

  • Prior zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC).
  • Prior maintenance or suppressive therapy for certain opportunistic infections, as follows:
  • Ganciclovir or foscarnet for CMV retinitis.
  • Fluconazole, amphotericin B, or flucytosine for cryptococcosis.
  • Amphotericin B for disseminated histoplasmosis.
  • Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis.
  • Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex.
  • Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Major, acute opportunistic infections.
  • Active neoplasms other than Kaposi's sarcoma or localized skin carcinoma.
  • Diabetes, congestive heart failure, clinical ascites, or uncontrolled hypertension.
  • Persistent grade 3/4 diarrhea.
  • Impaired oral intake, such as occurs with Candida esophagitis or severe mouth ulcers.
  • Clinically significant cardiac arrhythmias.
  • Requirement for anticonvulsants for seizure disorder.

Concurrent Medication:

Excluded:

  • Marijuana use.
  • Anabolic steroids.
  • Anticonvulsants for seizure disorders.
  • Alcohol or barbiturates.

Patients with the following prior conditions are excluded:

  • Diagnosis of a major, acute opportunistic infection within 2 months prior to study entry.
  • Hospitalization within 2 weeks prior to study entry.
  • History of hypersensitivity reactions to megestrol acetate, dronabinol, or sesame oil (a component of the dronabinol capsules).
  • History of thromboembolic events.
  • History of psychiatric disorder other than depression.

Prior Medication:

Excluded:

  • Prior dronabinol.
  • Megestrol acetate within 2 months prior to study entry.
  • Marijuana within 1 month prior to study entry.
  • Anabolic steroids within 3 months prior to study entry.

Current drug or alcohol abuse (patients with a history of occasional marijuana use are eligible provided they have abstained from its use for 1 month prior to study entry and agree to refrain from marijuana use for the study period).

Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00000737
Organization ID DATRI 004
Secondary IDs ††
Study Sponsor  National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators †† Roxane Laboratories
Bristol-Myers Squibb
Investigators 
Study Chair:     Galetto G        
Study Chair:     Egorin M        
Information Provided By National Institute of Allergy and Infectious Diseases (NIAID)
Verification Date January 1994
First Received Date  November 2, 1999
Last Updated Date August 22, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers